This HTML5 document contains 87 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n27http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00302/identifier/chebi/
n10http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00302/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00302/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00302/identifier/pdb/
n23http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00302/identifier/kegg-drug/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00302/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n26http://www.drugs.com/cdi/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00302/identifier/national-drug-code-directory/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00302
rdf:type
n3:Drug
n3:description
Antifibrinolytic hemostatic used in severe hemorrhage. [PubChem]
n3:dosage
n21:271B4E71-363D-11E5-9242-09173F13E4C5 n21:271B4E72-363D-11E5-9242-09173F13E4C5 n21:271B4E73-363D-11E5-9242-09173F13E4C5 n21:271B4E74-363D-11E5-9242-09173F13E4C5 n21:271B4E75-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
Biological half-life in the joint fluid is about 3 hours.
n3:indication
For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.
n3:manufacturer
n4:271B4E6C-363D-11E5-9242-09173F13E4C5 n4:271B4E6D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00302 n23:DB00302
dcterms:title
Tranexamic Acid
adms:identifier
n16:0013-1114-10 n17:AMH n18:D01136 n19:48669 n20:DB00302 n22:PA164750514 n24:Tranexamic_acid
n3:mechanismOfAction
Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.
n3:packager
n4:271B4E68-363D-11E5-9242-09173F13E4C5 n4:271B4E69-363D-11E5-9242-09173F13E4C5 n4:271B4E67-363D-11E5-9242-09173F13E4C5 n4:271B4E6A-363D-11E5-9242-09173F13E4C5 n4:271B4E6B-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Urinary excretion is the main route of elimination via glomerular filtration.
n3:synonym
Tranexmic acid Tranhexamic acid Acidum tranexamicum Tranexamsaeure Acide tranexamique Acido tranexamico trans-4-aminomethylcyclohexane-1-carboxylic acid trans-Tranexamic acid trans-4-(Aminomethyl)cyclohexanecarboxylic acid Cyklokapron trans-Amcha Trans AMCHA
n3:toxicity
Oral LD<sub>50</sub> in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.
n3:volumeOfDistribution
* 9 to 12 L
n9:hasAHFSCode
n10:20-28-16
n3:proteinBinding
The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen (does not bind serum albumin).
n3:synthesisReference
Noa Zerangue, Bernd Jandeleit, Yunxiao Li, "Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use." U.S. Patent US20070027210, issued February 01, 2007.
n11:hasConcept
n12:M0021767
foaf:page
n26:tranexamic-acid.html n27:cyclapron.htm
n3:IUPAC-Name
n8:271B4E7A-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B4E80-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B4E7F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B4E7C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B4E7D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B4E7E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B4E90-363D-11E5-9242-09173F13E4C5 n8:271B4E78-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B4E92-363D-11E5-9242-09173F13E4C5 n8:271B4E76-363D-11E5-9242-09173F13E4C5 n8:271B4E79-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B4E77-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n14:B02AA02
n3:H-Bond-Acceptor-Count
n8:271B4E86-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B4E87-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B4E81-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B4E82-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B4E84-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B4E83-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B4E85-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
1197-18-8
n3:category
n3:clearance
* 110 - 116 mL/min
n3:containedIn
n5:271B4E6F-363D-11E5-9242-09173F13E4C5 n5:271B4E70-363D-11E5-9242-09173F13E4C5 n5:271B4E6E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B4E8C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B4E8E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B4E8F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B4E91-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B4E8B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B4E8A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B4E8D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B4E7B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B4E88-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B4E89-363D-11E5-9242-09173F13E4C5